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In Brief Pease-Raissi et al. show that the antiapoptotic Bcl2 family protein Bclw plays a unique role in preventing IP 3 R1-dependent axon degeneration and that the chemotherapeutic agent paclitaxel diminishes trafficking and translation of bclw, thereby removing the brakes on this degenerative cascade.
SUMMARY
Chemotherapy-induced peripheral neuropathy (CIPN) is a debilitating side effect of many cancer treatments. The hallmark of CIPN is degeneration of long axons required for transmission of sensory information; axonal degeneration causes impaired tactile sensation and persistent pain. Currently the molecular mechanisms of CIPN are not understood, and there are no available treatments. Here we show that the chemotherapeutic agent paclitaxel triggers CIPN by altering IP 3 receptor phosphorylation and intracellular calcium flux, and activating calcium-dependent calpain proteases. Concomitantly paclitaxel impairs axonal trafficking of RNA-granules and reduces synthesis of Bclw (bcl2l2), a Bcl2 family member that binds IP 3 R1 and restrains axon degeneration. Surprisingly, Bclw or a stapled peptide corresponding to the Bclw BH4 domain interact with axonal IP 3 R1 and prevent paclitaxel-induced degeneration, while Bcl2 and Bclx L cannot do so. Together these data identify a Bclw-IP 3 R1-dependent cascade that causes axon degeneration and suggest that Bclw-mimetics could provide effective therapy to prevent CIPN.
INTRODUCTION
Axons that span long distances enable rapid communication within a neural circuit, but they are particularly vulnerable to degeneration. Axonal degeneration is a key feature of both neuronal pruning during development and of diverse neuropathological disorders. Molecular cascades governing pathological degeneration exhibit both commonalities with and differences from developmental axon degenerative cascades (Pease and Segal, 2014; Wang et al., 2012) . Pathological axon degeneration involves aberrant calcium signaling, changes in mitochondrial function, and activation of calpain proteases. Bcl2 family members, which are implicated in developmental axon pruning (Cosker et al., 2013 (Cosker et al., , 2016 Courchesne et al., 2011; Pazyra-Murphy et al., 2009; Schoenmann et al., 2010; Simon et al., 2012 Simon et al., , 2016 Vohra et al., 2010) , are capable of regulating mitochondrial morphology and calcium homeostasis (Chipuk et al., 2010) . However, it is not yet known whether pathological axon degeneration involves Bcl2 components. Therapies targeting Bcl2 family members exhibit great promise in preclinical and clinical studies (Anderson et al., 2016; Bodur and Basaga, 2012; Konopleva et al., 2016; LaBelle et al., 2012; Walensky et al., 2004; Weyhenmeyer et al., 2012) , and so identification of Bcl2 family members involved in axon degenerative processes could provide a molecular handle to understand and prevent pathological degenerative cascades.
Many cancer therapies cause axon injury and neurological impairment, resulting in chemotherapy-induced peripheral neuropathy (CIPN). In patients with CIPN, degeneration of long peripheral sensory or motor neuron axons causes pain, tingling, numbness, and/or impaired motor function. Chemotherapeutic drugs that cause CIPN include platinum drugs, vinca alkaloids, and taxanes such as paclitaxel. Paclitaxel, a microtubule stabilizing agent commonly used to treat patients with breast, ovarian, lung, or other cancers, causes a primarily sensory neuropathy (Gornstein and Schwarz, 2014) . It has been suggested that paclitaxel elicits a degenerative cascade similar to that observed after mechanical axon injury (Fukuda et al., 2017; Gornstein and Schwarz, 2014; Wang et al., 2002 Wang et al., , 2004 . However, the molecular mechanism for paclitaxel-induced degeneration is not understood, and there are currently no treatments available for this common disorder. As CIPN often necessitates reducing the dose of chemotherapeutic drugs, it both limits the ability to treat many cancers and also causes severe disability for cancer survivors.
Here we use in vitro and in vivo systems to analyze the pathological effects of paclitaxel on dorsal root ganglia (DRG) sensory neurons. Our data indicate that paclitaxel acts directly on axons of sensory neurons to alter inositol 1,4,5-trisphosphate receptor (IP 3 R) activity and initiate axon degeneration. We show that paclitaxel treatment selectively reduces axonal expression of the Bcl2 family member Bclw (Bcl2l2) by impairing axonal trafficking of RNA transport granules containing bclw mRNA and the RNA-binding protein SFPQ, thus inhibiting bclw translation.
Moreover, the BH4 domain of Bclw binds IP 3 R1 and thereby prevents paclitaxel-induced axonal degeneration, a function that is not shared by Bcl2 or Bclx L . Together these findings identify a mechanism for CIPN and demonstrate that the underlying axonal degenerative process partially overlaps with critical cascades triggered by developmental pruning or traumatic injury. Importantly, these studies suggest that Bclw BH4-mimetics may provide a clinically useful preventative therapy for CIPN and other disorders of axonal degeneration.
RESULTS

Paclitaxel Causes Axon Fragmentation and Initiation of an Axon Degenerative Cascade
While recent reports suggest that paclitaxel acts directly on axons to reduce axon length (Yang et al., 2009 ) and impair outgrowth (Gornstein and Schwarz, 2017) , it is not yet established whether paclitaxel directly impacts sensory axons to cause degeneration, or whether degeneration represents an indirect consequence of paclitaxel affecting other components of the sensory circuitry (Jin et al., 2008; Kiya et al., 2011; Li et al., 2014; Peters et al., 2007a; Peters et al., 2007b; Yang et al., 2009; Zhang et al., 2012) . To determine the subcellular site of action for paclitaxel-induced degeneration, we introduced paclitaxel (30 nM) into the media surrounding either cell body or distal axon compartments of embryonic day 15 (E15) DRG sensory neurons in compartmented cultures and analyzed paclitaxel-induced axonal fragmentation, a direct readout of degeneration (Sasaki et al., 2009) . We find that paclitaxel added to axons increases axon degeneration, while paclitaxel added to cell bodies has no effect ( Figures 1A and 1B) . Notably, paclitaxel treatment of either subcellular compartment did not induce cell body apoptosis as assessed by nuclear condensation ( Figures  1C and 1D) .
Following traumatic axon injury, calcium dysregulation is a critical step that alters mitochondrial function and activates calpain proteases to induce axon degeneration (Barrientos et al., 2011; Villegas et al., 2014; Wang et al., 2012) . Similarly, paclitaxel applied to axons reduced both axonal mitochondrial membrane potential as assessed by the voltage-sensitive dye TMRE ( Figure 1E ) and axonal mitochondrial length (Figures 1F and 1G ; average axonal mitochondrial length 0.92 ± 0.01 mm [DMSO], 0.7 ± 0.04 mm [paclitaxel], p < 0.05 by Student's t test), and also increased calpain activity in a dose-dependent manner ( Figure 1H ). Furthermore, calpain inhibitor III (20 mM to axons) prevented paclitaxel-induced degeneration, indicating that axon fragmentation requires local calpain activation ( Figure 1I ). Together these results indicate that paclitaxel acts locally and directly on sensory neuron axons to initiate a degenerative process that culminates in calpain-dependent axonal fragmentation.
Paclitaxel Impedes Axonal Localization of RNA Transport Granules and Reduces bclw Translation Although anti-apoptotic Bcl2 family members are involved in developmental axon degeneration, it is uncertain whether Bcl2 family members are also critical for axon degeneration caused by injury or disease (Cosker et al., 2013; Courchesne et al., 2011; Nikolaev et al., 2009; Pazyra-Murphy et al., 2009; Schoenmann et al., 2010; Simon et al., 2012 Simon et al., , 2016 Vohra et al., 2010) . To determine whether Bcl2 family members are implicated in paclitaxel-induced axon degeneration, we examined expression of the anti-apoptotic components Bclw (Bcl2l2), Bcl2, or Bclx L (Bcl2l1) after paclitaxel treatment. Since Bclw protein can be locally translated in axons (Cosker et al., 2013) , we examined both mRNA and protein expression. Strikingly, paclitaxel treatment reduced both Bclw mRNA and protein levels selectively in axons and did not alter mRNA transcripts or protein expression in cell bodies (Figures 2A-2C ). In contrast, paclitaxel treatment did not change Bcl2 and Bclx L mRNA or protein in axons or in cell bodies ( Figures 2D-2I) .
The RNA-binding protein SFPQ binds and transports bclw mRNA to the axon (Cosker et al., 2016) , where it is locally translated into Bclw protein (Cosker et al., 2013) . To determine whether paclitaxel reduces axonal Bclw levels by hindering this sequence of events, we examined SFPQ expression after paclitaxel treatment. Paclitaxel caused a reduction in axonal SFPQ levels, without significantly altering SFPQ expression in the cell body compartment (Figures 3A and 3B) , suggesting that paclitaxel impedes transport of SFPQ-containing RNA granules to axons. To ask whether the decrease in SFPQ causes axon degeneration, we virally expressed a FLAG-tagged version of SFPQ ( Figure S1 ) prior to paclitaxel treatment. Expression of exogenous SFPQ maintained axonal quantities of SFPQ and of Bclw ( Figures 3C and 3D) , and thereby prevented paclitaxelinduced axon degeneration ( Figure 3E ). As SFPQ is critical for intracellular transport and axonal translation of bclw mRNA (Cosker et al., 2016) , we performed metabolic-labeling experiments to determine whether paclitaxel specifically alters Bclw protein synthesis. The non-canonical amino acid azidohomoalanine (AHA) was used to label nascent proteins of DRG neurons in mass cultures that were treated with paclitaxel or a vehicle control for 3 or 9 hr. Paclitaxel treatment dramatically reduced synthesis of AHA-labeled Bclw. In contrast, paclitaxel treatment did not alter synthesis of AHA-labeled Bcl2 protein (Figures 3F and 3G) . Thus, paclitaxel treatment of sensory neurons specifically impairs bclw translation. Together these data suggest that paclitaxel, a microtubule-stabilizing agent, diminishes axonal transport of SFPQ and its cargo, bclw mRNA, and thereby decreases Bclw synthesis.
Bclw Prevents Paclitaxel-Induced Degeneration
If paclitaxel-induced reduction of axonal Bclw leads to degeneration, then sustained Bclw levels in axons should prevent degeneration. Therefore, we asked whether paclitaxel-induced degeneration can be prevented by recombinant Bclw, Bcl2, or Bclx L protein introduced selectively into axons of sensory neurons grown in compartmented cultures (Cosker et al., 2013) . Bclw, introduced into axons, completely prevented paclitaxel-induced axon degeneration ( Figure 4A , 4B, and S2). While both Bclw and Bclx L regulate developmental neurotrophin-dependent axon survival (Cosker et al., 2013 (Cosker et al., , 2016 Simon et al., 2016) , we find that neither Bclx L nor Bcl2 prevents paclitaxel-induced degeneration even when protein is introduced directly into axons (Figure 4A, 4B, and S2) . Furthermore, selective introduction of Bclw, Bcl2, or Bclx L protein into cell bodies did not inhibit paclitaxel-induced degeneration ( Figure 4C ). As calpain proteases are required for paclitaxel-induced degeneration, we analyzed the ability of Bclw to prevent calpain activation. We found that paclitaxel-induced calpain activation was selectively prevented by Bclw protein. Again, Bcl2 and Bclx L protein were not able to prevent calpain activation ( Figure 4D ). Together these data indicate that paclitaxel-induced reduction in Bclw expression promotes axon fragmentation and identify Bclw as a specialized Bcl2 family member that functions locally in axons in a cascade that prevents calpain activation and degeneration.
The BH4 Domain of Bclw Is Sufficient to Prevent Degeneration Bclw, Bcl2, and Bclx L exhibit highly conserved structures with four characteristic Bcl2 homology (BH) domains. The BH4 domains mediate multiple anti-degenerative effects of these proteins Donnini et al., 2009; Hotchkiss et al., 2006; Mincheva-Tasheva et al., 2014; Monaco et al., 2015; Rong et al., 2009; Shimizu et al., 2000; Sugioka et al., 2003) . While the BH4 domains of Bclw, Bcl2, and Bclx L exhibit a x e d n I n o i t a r e n e g e D Figure 5A ). SAHBs are a-helical hydrocarbon stapled peptides that are bioactive, protease resistant, and cell permeable Walensky and Bird, 2014) . As described previously for Bcl2 BH4 SAHB A , Bclw BH4 SAHB A inhibited Bax-mediated membrane poration of encapsulated liposomes in a dose-dependent manner, indicating that this Bclw-mimetic has functional activity ( Figure 5B ). We transfected FITC-tagged BH4 peptides of Bclw, Bcl2, or Bclx L or a vehicle control into axons of compartmented cultures before treating axons with paclitaxel for 24 hr ( Figure 5C ). All three FITC-labeled peptides were detectable in axons and exhibited a punctate distribution. As observed with full-length Bclw, the Bclw BH4 SAHB A prevented paclitaxel-induced axon degeneration. In contrast, Bcl2 BH4 SAHB A and Bclx L BH4 SAHB A did not do so ( Figure 5D ). Importantly, equivalent intracellular bioactivity of these peptides in sensory neurons was confirmed using a neurotrophin-deprivation assay; transfection of Bclw BH4, Bcl2 BH4, or Bclx L BH4 SAHB peptides into cell bodies equally prevented apoptosis triggered by 24 hr of neurotrophin deprivation ( Figure 5E ). Together these results indicate that the BH4 domain of Bclw prevents paclitaxel-induced axon degeneration, a function that is not shared by the BH4 domains of Bcl2 and Bclx L .
Bclw Regulates IP 3 R1 to Prevent Axon Degeneration
The unexpectedly distinctive role of Bclw and its BH4 domain in preventing paclitaxel-induced degeneration suggests that the Bclw BH4 domain may interact with different molecular targets than Bcl2 and Bclx L do in the axonal context. In addition to pro-apoptotic Bcl2 family members such as Bax, BH4 domains can also interact with inositol 1,4,5-trisphosphate receptors (IP 3 Rs) such as IP 3 R1 (Chang et al., 2014; Distelhorst and Bootman, 2011; Greenberg et al., 2014; Oakes et al., 2005; Rong et al., 2009) . Notably, IP 3 R1 has been implicated in injuryinduced axon degeneration (Villegas et al., 2014) . We examined co-precipitation of the biotinylated BH4 SAHB peptides with IP 3 R1 from sensory neurons. Surprisingly, IP 3 R1 from axons preferentially interacted with Bclw BH4 SAHB A (Figures 6A and 6B), while IP 3 R1 from cell bodies interacted similarly with all three SAHBs ( Figures 6C and 6D ). Furthermore, biotinylated SAHBs for Bclw, Bcl2, and Bclx L all associated equally with the proapoptotic protein Bax, whether derived from axons or cell bodies. None of the SAHBs associated with a negative control protein in lysates from either axons or cell bodies (tyrosyl-tRNA synthetase, YARS, which is present at similar levels in both compartments; Figures 6A-6D ). Together these results identify axonal IP 3 R1 as a molecular partner that selectively binds to the BH4 domain of Bclw and may be responsible for the specialized ability of Bclw to prevent axon degeneration.
IP 3 Rs are resident endoplasmic reticulum (ER) calcium channels that control calcium release from intracellular stores. To determine whether paclitaxel alters IP 3 R functionality, we stimulated DRG neurons expressing the calcium indicator GCaMP6s with ATP to trigger production of the IP 3 R ligand IP 3 and thereby induce IP 3 R-dependent calcium release from the ER. Paclitaxel treatment for 24 hr significantly reduced ATP-evoked IP 3 R calcium release ( Figure 6E ), consistent with previous reports (Boehmerle et al., 2007) . This finding suggests that paclitaxel either alters IP 3 R activity or reduces intracellular calcium store levels. To distinguish between these possibilities, we examined intracellular calcium content by treating GCaMP6s-expressing cells with thapsigargin, a sarcoendoplasmic reticulum calcium ATPase (SERCA) inhibitor that induces calcium efflux from intracellular stores. Paclitaxel treatment did not alter thapsigarginmediated calcium release ( Figure 6F ), indicating that paclitaxel alters IP 3 R activity rather than affecting the magnitude of intracellular calcium stores. Paclitaxel-induced changes in IP 3 R activity have been attributed to paclitaxel-mediated degradation of the IP 3 R modulatory protein neuronal calcium sensor 1 (NCS-1) (Boehmerle et al., 2007) . However, we did not observe changes in the level of NCS-1 in response to paclitaxel treatment ( Figure S3A ). Changes in IP 3 R1 phosphorylation state have also been shown to modulate IP 3 R1 activity, as increased phosphorylation at serine 1756 (rat Ser1756; mouse Ser1755) correlates with increased sensitivity to IP 3 (Nakade et al., 1994; Oakes et al., 2005; Tang et al., 2003; Vanderheyden et al., 2009; Wagner et al., 2003 Wagner et al., , 2004 . Paclitaxel treatment for 24 hr lowered axonal Ser1756 phosphorylation, a finding consistent with evidence that paclitaxel reduces IP 3 -gated ER calcium flux ( Figure 6G ). To address the importance of IP 3 R1 activity for paclitaxel-induced axon degeneration, we used shRNA to reduce IP 3 R1 in sensory neurons and then assessed the response to paclitaxel. We find that knockdown of IP 3 R1 ( Figure S3B ) prevents paclitaxel-induced degeneration ( Figure 6H ). Together these results ; data normalized to actin; *p < 0.05 by one-way ANOVA with Bonferroni correction; n = 3; data represent mean ± SEM. See also Figure S1 . (E) Degeneration index of axons treated with paclitaxel or vehicle following infection with hsSFPQ or Cntrl lentivirus; *p < 0.05 by one-way ANOVA; n = 3 independent experiments (20-25 images); data represent mean ± SEM. (F and G) Western blot (F) and quantification of Bclw, Bcl2, or actin proteins showing input lysate and biotin pull-down of newly synthesized proteins in mass cultures after 0, 3, or 9 hr of simultaneous AHA labeling and paclitaxel or DMSO vehicle control treatment (G); data normalized to vehicle control; *p < 0.05 by z test; n = 4; data represent mean ± SEM; samples for control and paclitaxel were run on same gel and are from the same exposure.
indicate that paclitaxel treatment activates a conserved pathological axon degenerative cascade that is dependent on IP 3 R1 and culminates in activation of calpain proteases. To determine whether Bclw and IP 3 R1 function in the same pathway to regulate axon degeneration, we infected neurons with shRNAs targeting Bclw and/or IP 3 R1 ( Figure S3C ). Acute knockdown of Bclw increased spontaneous axonal degeneration and exacerbated paclitaxel-induced degeneration (Figure 6H ), indicating that endogenous Bclw functions as a brake on a degenerative cascade activated by paclitaxel. Moreover, IP 3 R1 knockdown completely prevented axon degeneration caused by Bclw knockdown or by paclitaxel, either individually or together ( Figure 6H ). Together these data indicate that Bclw functions upstream of IP 3 R1 to prevent an axonal degenerative cascade that is triggered by paclitaxel.
The balance of anti-apoptotic and pro-apoptotic Bcl2 family members has been shown to regulate IP 3 R1 phosphorylation and calcium dynamics. Bax, which binds to Bclw in axons (Figures 6A-6D ), reduces IP 3 R1 calcium leak and Ser1756 phosphorylation (Oakes et al., , 2005 , and this functionality is distinct from the regulation of mitochondrial cytochrome c release. Since we observe a paclitaxel-induced decrease in IP 3 R1 phosphorylation at Ser1756 (Figure 6G ), we asked whether Bax is involved in axon degeneration caused by paclitaxel. Acute knockdown of Bax ( Figure S3D ) decreased paclitaxel-induced degeneration ( Figure 6I ). However, paclitaxel did not induce cytochrome c release from axonal mitochondria, as assessed by persistent cytochrome c colocalization with MitoTracker-labeled mitochondria after paclitaxel treatment ( Figures  S4A and S4B) . As a positive control, we verified our capacity to visualize the decrease in mitochondrial cytochrome c immunostaining upon treatment with a pro-apoptotic kinase inhibitor K252A ( Figure S4C ). Taken together, our data suggest that Bax may be involved in paclitaxel-induced degeneration through action at the ER rather than its classical function in regulating mitochondrial outer membrane poration and cytochrome c release.
Loss of Bclw Exacerbates Paclitaxel-Induced Neuropathy In Vivo
To examine the protective role of Bclw in paclitaxel-induced degeneration in vivo, we injected 2-month-old bclw+/+ and bclwÀ/À mice with paclitaxel (4 mg/kg every other day for 8 days), a dose that mimics clinical protocols for paclitaxel therapy, or with a vehicle control. At this age, untreated bclwÀ/À mice exhibit normal epidermal innervation and sensory behavior (Courchesne et al., 2011) . Consistent with prior studies in wildtype mice, both bclw+/+ and bclwÀ/À mice develop thermal hyperalgesia after paclitaxel treatment as measured by paw withdrawal in a 50 C hot-plate test ( Figure 7A ). However, the thermal pain sensitivity observed in bclwÀ/À mice after paclitaxel treatment was more severe than seen in age-matched bclw+/+ mice ( Figure 7A ). Both bclw+/+ and bclwÀ/À mice develop severe mechanical allodynia, as assessed by withdrawal responses to von Frey filaments ( Figure 7B ). In patients, paclitaxel causes a primarily sensory neuropathy with little to no motor symptoms (Gornstein and Schwarz, 2014); similarly, paclitaxel-treated mice have normal motor function as assessed by an accelerating RotaRod test ( Figure S5 ). The gold standard for diagnosis of CIPN is reduced intraepidermal innervation. Therefore, we examined intraepidermal nerve fibers of the hindpaw after paclitaxel or control treatments. Strikingly, we found that bclwÀ/À mice treated with paclitaxel exhibit a greater reduction in intraepidermal nerve fiber number in both thick (dermal papillae-containing; Figures 7C and  7D ) and thin (non-dermal papillae containing; Figures 7E and 7F ) skin than that detected in bclw+/+ mice. Together, these data demonstrate that Bclw functions to protect sensory axons from paclitaxel-induced degeneration in vivo as well as in vitro.
DISCUSSION
In this study, we use compartmented culture and in vivo systems to investigate the mechanisms underlying CIPN, and we demonstrate that paclitaxel acts directly on sensory axons to induce a Bclw-IP 3 R1-dependent degenerative cascade. While previous studies highlighted the importance of the Bcl2 family in regulating caspase pathways and preventing developmental axon degeneration (Cosker et al., 2013; Cusack et al., 2013; Nikolaev et al., 2009; Schoenmann et al., 2010; Simon et al., 2012) , here we identify a novel axon survival mechanism involving specific interactions between Bclw and axonal IP 3 R1. Our results indicate that paclitaxel selectively reduces axonal Bclw levels by inhibiting transport of RNA granules containing the RNA-binding protein SFPQ and so impedes bclw mRNA axonal localization and translation. Therefore paclitaxel-induced degeneration can be prevented by replenishing axonal stores of Bclw. Importantly, Bclw has a unique ability to protect axons from degeneration. Neither Bcl2 nor Bclx L prevents paclitaxelinduced degeneration, and paclitaxel does not alter the expression of these closely related Bcl2 homologs. Furthermore, the BH4 domain of Bclw, which selectively interacts with axonal IP 3 R1, is sufficient for these specific protective effects. Together, these data indicate that paclitaxel causes neuropathy by reducing axonal Bclw, thus deregulating IP 3 R1 signaling and permitting activation of IP 3 R1-dependent degeneration. The mechanism of action for paclitaxel is to prevent microtubule depolymerization and so enhance microtubule stability. Based on this activity, a prevalent hypothesis has been that paclitaxel reduces axonal transport of mitochondria (Gornstein and Schwarz, 2014; Shemesh and Spira, 2010) . However, a recent study (Gornstein and Schwarz, 2017) demonstrates that paclitaxel causes retraction of sensory axons without reducing mitochondrial movement. We find that paclitaxel decreases axonal levels of SFPQ, an RNA-binding protein required for axonal trafficking of bclw mRNA, reduces bclw translation, and so results in decreased levels of Bclw protein in axons. These changes in axonal transport due to paclitaxel are functionally important in CIPN, as increased expression of SFPQ or of Bclw prevents paclitaxel-induced degeneration. Together, our data indicate that, rather than causing a global reduction in microtubule-based transport, paclitaxel selectively impinges on axonal transport of RNA granules (Bobylev et al., 2015) and thereby reduces translation of specific transcripts, including bclw, causing axonal degeneration.
Intriguingly, Bclw has a specialized ability to prevent paclitaxel-induced degeneration of sensory axons, a functionality not shared by the closely related Bcl2 or Bclx L proteins. This specialized role for Bclw is particularly surprising because Bclx L , as well as Bclw, were recently shown to promote neurotrophindependent sensory axon survival (Cosker et al., 2013; Simon et al., 2016) . During developmental axon degeneration, both Bclw and Bclx L prevent degeneration by binding and inhibiting the pro-apoptotic Bcl2 family members Bax and Puma (Simon et al., 2016) . In contrast, in paclitaxel-induced axon degeneration, Bclw functions as a specialized upstream regulator of axonal IP 3 R1. Thus, unlike closely related family members, Bclw has a distinctive ability to interact with IP 3 R1 in axons and exhibits a unique ability to protect axons from paclitaxel toxicity.
In addition to causing a reduction in axonal Bclw mRNA and protein, we find that paclitaxel alters sensory neuron calcium dynamics, a critical component in pathological axon degeneration ( Figure 6E ) Bobylev et al., 2015; Boehmerle et al., 2007; Chen et al., 2015; Mo et al., 2012; Yilmaz and Gold, 2015) . While it is well accepted that a rise in axonal calcium is necessary for calpain activation and for axon degeneration, the source and trigger of this calcium increase are not clear. Early studies indicated a role for extracellular calcium influx (George et al., 1995; Schlaepfer and Bunge, 1973) ; however, more recent reports suggest that calcium from intracellular stores can also initiate calpain activation and axon degeneration following mechanical or toxic injury (Villegas et al., 2014) . Our studies begin to delineate a pathway whereby paclitaxel deregulates IP 3 R1 function and so alters intracellular calcium dynamics, ultimately resulting in elevated cytoplasmic calcium and calpain activation (Figure 8) .
The decrease in IP 3 -induced calcium release into the cytoplasm that we observed after 24 hr of paclitaxel treatment may reflect complex changes in location or timing of intracellular calcium dynamics. Our assay monitors overall IP 3 -induced calcium release into the cytoplasm through IP 3 R1, 2, and 3 ( Figure 6E the observed reduction in cytoplasmic calcium release may be associated with localized, increased calcium flux at mitochondrial-associated membranes where IP 3 R1 is clustered (Krols et al., 2016; Raturi and Simmen, 2013) . Alternatively, early increases in calcium release from intracellular stores may be followed by a homeostatic decrease in IP 3 -induced calcium release into the cytoplasm (Berridge et al., 2000) , resulting in the altered calcium dynamics observed after 24 hr of paclitaxel treatment ( Figure 6E ). Together our data indicate that paclitaxel alters IP 3 R function and intracellular calcium dynamics in a complex fashion and that IP 3 R1 is required for paclitaxel-induced degeneration.
Our findings suggest that axonal IP 3 R1 interacts in a specialized manner with Bclw and that these interactions are critical for the biological function of Bclw in promoting axonal survival. Although the native structures of the BH4 domains bound to their protein targets have not been fully defined, amino acid sequence and structure-based differences could underlie alternate binding and biological activities among Bcl2, Bclx L , and Bclw. Three distinct sites on IP 3 R1 have been identified as potential binding sites for the BH4 domain of Bcl2 family members (Bonneau et al., 2016; Rong et al., 2009; Schulman et al., 2013) . Detailed analysis of the binding site(s) on IP 3 R1 that are available within axons and of the molecular features that enable selective interactions with the Bclw BH4 SAHB may provide an approach for developing new therapies for CIPN.
We find that mice with genetic ablation of Bclw exhibit enhanced sensitivity to paclitaxel, suggesting that Bclw functions to limit paclitaxel-induced degeneration in vivo. Paclitaxel-induced thermal hyperalgesia and axon loss was enhanced in bclwÀ/À mice compared with their wild-type littermates. Importantly, this enhanced response is observed in 2-to 3-month-old bclwÀ/À mice that do not display the axon degeneration and thermal hypoalgesia observed in 4-to 8-month-old bclwÀ/À mice (Courchesne et al., 2011) . It is possible that axons of young bclwÀ/Àmice are impaired prior to paclitaxel treatment and that any mutation that causes neuropathy may enhance the effects of paclitaxel. However, paclitaxel does not simply accelerate the progressive neuropathy observed with increased age in bclwÀ/À mice, since enhanced response to thermal stimulation is observed with paclitaxel while decreased response to thermal stimulation was observed in older bclwÀ/À mice. Thus, while our studies suggest a protective role for Bclw in paclitaxel-induced degeneration, future studies will be required to determine the therapeutic relevance of restoring Bclw function to prevent paclitaxel-induced neuropathy in patients.
Based on our studies, we propose a model in which paclitaxel attenuates axonal transport and translation of bclw in long axons and thereby removes the brakes on an axonal degenerative cascade (Figure 8 ). As paclitaxel enhances axon degeneration even in the absence of Bclw ( Figures 6H  and 7A-7F) , paclitaxel may initiate additional pro-degenerative signals including changes in IP 3 R1 phosphorylation state and activity. Strikingly, knockdown of IP 3 R1 completely prevents paclitaxel-induced degeneration either in the presence or absence of Bclw, indicating that IP 3 R1 functions downstream of Bclw to enable calpain-dependent degeneration. Together, these studies suggest that Bclw inhibits the pro-degenerative effects of IP 3 R1 activity. As genetic ablation of the pro-degenerative molecule Sarm1 prevents paclitaxel-induced neuropathy (Turkiew et al., 2017) , there is an intriguing possibility for intersection between the Sarm1-MAPK degenerative pathway (Yang et al., 2015) and the SFPQ-Bclw-IP 3 R1 cascade identified here.
Our studies further reveal that Bax contributes to paclitaxelinduced degeneration. Bax is most well-known for its function at the mitochondria, where it mediates mitochondrial membrane poration to induce cytochrome c release and activation of the caspase cascade. However, paclitaxel treatment does not induce cytochrome c release, suggesting that Bax may play a different role in paclitaxel-induced degeneration. Notably, Bax is also present in the ER, where it alters IP 3 R1 phosphorylation state and modulates ER calcium dynamics Scorrano et al., 2003; Zong et al., 2003) . These changes in calcium dynamics may represent the critical function of Bax in the context of CIPN. Although Bclx L and Bcl2 full-length proteins or BH4 SAHB domains all bind Bax and prevent Bax-mediated apoptosis ( Figures 5E and 6A-6D ) Petros et al., 2004) , they do not prevent paclitaxel-induced degeneration. Thus, compounds such as Bclw BH4 SAHBs that mimic Bclw interactions with IP 3 R1 without impinging on the ability of Bax to initiate axonal cytochrome c release may provide a promising therapeutic strategy for CIPN.
Despite the prevalence and morbidity of CIPN, at present there are no methods to prevent or reverse this disorder (Brewer et al., 2016; Cavaletti and Marmiroli, 2010; Pachman et al., 2011) . Current treatment options therefore are to reduce or discontinue chemotherapy and to offer non-specific symptomatic pain relief. In rodent models, systemic calpain inhibition reduces the neurotoxic effects of paclitaxel in vivo (Wang et al., 2004) , and calcium chelation reduces paclitaxel-induced neuropathic pain (Siau and Bennett, 2006 ). Here we show that a stabilized alpha-helix of the Bclw BH4 domain binds to IP 3 R1 and prevents paclitaxel-induced calpain activation and degeneration, indicating this designer peptide provides a promising template for drugs that can prevent CIPN. IP 3 R1 is also required for axon degeneration induced by other chemotherapeutic agents (Villegas et al., 2014) , and alterations in calcium are implicated in axon degeneration due to diverse causes (Coleman, 2005) . Therefore, reduction in Bclw and consequent activation of IP 3 R1-dependent axonal fragmentation may represent a conserved mechanism for many neurodegenerative syndromes.
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Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Rosalind Segal (rosalind_segal@dfci.harvard.edu). AAV9 viral vectors were obtained from the Penn Vector Core and require an MTA.
MOUSE LINES AND ANIMAL CARE
All experimental procedures were conducted in accordance with the National Institutes of Health guidelines and were approved by the Dana-Farber Cancer Institutional Animal Care and Use Committee.
Timed pregnant Sprague-Dawley rats were purchased from Charles River. bclwÀ/À mice were a generous gift from Grant MacGregor (University of California, Irvine, CA; (Ross et al., 1998) . Genotyping for the wild-type bclw gene and/or lacZ gene were performed by Transnetyx using the Bclw targeting sequence GCTCTGAACCTCCCCATGACTTAAATCCGTTGCTCTTTCT-TGGCC CTGCCCAGTGCCTCTGAGCATTTCACCTATCTCAGGAGC and the lacZ sequence CGATCGTAATCACCCGAGTGTGATCATCTG GTCGCTGGGGAATGAGTCAGGCCACG-G. bclwÀ/À mice were maintained on a C57BL/6JEiJ background (Navarro et al., 2012) .
Cell culture
Compartmented chamber (Campenot) cultures were prepared as described previously (Fenstermacher et al., 2015) with modifications. Briefly, DRGs from embryonic day 15 (E15) rats of either sex were dissected and trypsinized. DRG neurons (1.2 3 10 5 cells) were plated in the center compartment of a Teflon divider (Camp10, Tyler Research; Campenot, 1982) affixed to a p35 culture dish coated with growth factor reduced Matrigel basement membrane (1:45 in DMEM; BD Biosciences). Cultures were maintained in media consisting of Neurobasal (Invitrogen) with 2% B27 supplement (Invitrogen), 1% penicillin-streptomycin, 1% GlutaMAX (Life Technologies), 0.08% glucose, and 0.3 mM cytosine arabinoside (AraC) at 37 C, 7.5% CO 2 ; BDNF + NGF (PeproTech)
were added to the cell body compartment at a concentration of 10 ng/mL and to the axon compartment at a concentration of 100 ng/mL for 2 days. On day 3, media was replaced and the AraC was omitted. On day 5 neurotrophins were removed from the cell body compartment and reduced to 1 ng/mL in the axon compartments for 3-5 days. For paclitaxel treatment experiments, 30 nM paclitaxel (Sigma-Aldrich) or vehicle control (0.1% DMSO) was added to either cell body or distal axon compartments on day Microfluidic chambers cultures were prepared as described previously (Fenstermacher et al., 2015) , with modifications. Briefly, 3 3 10 4 E15 DRG neurons (4 mL volume) were plated into one channel of a microfluidic device (Xona Microfluidics, SND450) affixed to a PDL/laminin-coated cover glass (Fisherbrand Microscope Cover Glass; 24 3 40-1.5). Cells were plated in Neurobasal media (described above) with 0.3 mM AraC; 50 ng/mL NGF + BDNF was added to cell body wells, and 100 ng/mL was added to axon wells. On day 2, cell body neurotrophins were reduced to 10 ng/mL. On day 4 or 5, cell body neurotrophins were reduced to 1 ng/mL and axon neurotrophins were reduced to 10 ng/mL, and cultures were maintained for 1-3 more days. For paclitaxel treatment experiments, 60 nM paclitaxel or vehicle control was added to the distal axon compartment for 24-48 hr to observe changes in axons. Non-compartmented, mass cultures consisting of 3 3 10 5 E15 DRG neurons were grown on Matrigel-coated p35 culture dishes in neurotrophin-enriched (100 ng/mL NGF + BDNF) media with 0.3 mg/mL AraC. On day 3, neurotrophins were reduced to 10 ng/mL) and cultures maintained for 3-6 more days. To observe changes in calcium signaling or translation levels, 600 nM paclitaxel was added globally to cultured neurons. Higher doses are required for cultures that contain cell bodies and so include greater cellular material, only a small portion of which is axonal. 600 nM paclitaxel causes degeneration and significantly increases calpain activity in mass cultures ( Figure 1H ), but calpain activation can still be prevented by expression of the Bclw BH4 SAHB A (Figure 4D ), suggesting the same Bclw-calpain pathway is engaged as with 30 nM paclitaxel.
METHODS DETAILS Axonal degeneration assay
Compartmented chamber cultures were fixed at room temperature with 4% PFA diluted 1:2 in media for 10 min, then undiluted 4% PFA for an additional 20 min. Cultures were permeabilized with 0.1% Triton X-100 for 10 min, blocked in 3% BSA and 0.1% Triton X-100 for 1 hr at room temperature, and incubated with mouse anti-Tuj1 (1:400; clone Tuj1; Covance) overnight at 4 C. Cultures were then incubated with goat anti-mouse AlexaFluor (1:1000; Invitrogen) for 1 hr at room temperature and counterstained with DAPI. Images of distal axon tips were obtained using a 40X air objective, and axonal degeneration was quantified as a degeneration index, as previously described (Cosker et al., 2013; Sasaki et al., 2009) . Apoptosis analysis was carried out on the same cultures by taking images in the cell body compartment and counting total and condensed nuclei in NIH ImageJ software by an observer blind to condition.
Mitochondrial membrane potential measurements E15 DRG neurons grown in microfluidic cultures were treated with 60 nM paclitaxel to the axonal compartment for 48 hr, then labeled using Tetramethylrhodamine ethyl ester (TMRE) (Invitrogen). TMRE was applied (10 nM) for 20 min at 37 C, then cells were rinsed with phenol-free media and imaged live using a 60x oil 1.4NA objective. Fluorescence intensity of axonal mitochondria was measured by dividing the fluorescence intensity of each mitochondria (Fm) by the background fluorescence intensity of a nearby cytoplasmic region (Fc). Fluorescence intensity was measured using NIH ImageJ software by an observer blind to condition.
Mitochondrial length measurements E15 DRG neurons grown in microfluidic cultures were treated with 60 nM paclitaxel to the axonal compartment for 48 hr, and fixed at room temperature with 4% PFA diluted 1:2 in media for 10 min, then undiluted 4% PFA for an additional 10 min. Cultures were permeabilized and blocked as above and incubated overnight at 4 C with the following antibodies: anti-Tomm20 (1:300; Abcam), and anti-Tuj1. Cultures were then stained with AlexaFluor antibodies and counterstained with DAPI as above. Images were acquired throughout the axon compartment using a 60x 1.4NA oil objective, and Tomm20 mitochondrial length was measured manually using NIH ImageJ by an experimenter blind to condition. 1078 (vehicle) and 1049 (paclitaxel) axonal mitochondria were measured across three independent experiments.
Quantitative reverse transcription-PCR RNA was extracted from DRG neurons in compartmented cultures using TRIzol (Invitrogen) according to manufacturer's protocol. Reverse transcription (RT) was performed using the cDNA archive kit (Applied Biosystems) according to the manufacturer's protocol, and quantitative real-time RT-PCR was performed using Taqman Gene expression assays (Applied Biosystems) to analyze expression of bclw (Rn00821025_g1), bcl2 (Rn99999125_m1), and bclx L (Rn00580568_g1). Data were normalized to gapdh (glyceraldehyde-3-phosphate dehydrogenase; Applied Biosystems) for each sample.
Western blot
For analysis of Bcl2 family proteins, SFPQ, and IP 3 R1 phosphorylation, cell bodies and axons of E15 DRGs in compartmented cultures were lysed in nonionic detergent, lysates were separated by 4%-12% Bis-Tris or 3%-8% Tris-Acetate SDS-Page (Thermo Fisher Scientific), and probed with the following antibodies: anti-Bclw (1:1000; clone 31H4; Cell Signaling Technology), anti-Bcl2 (1:1000; Abcam), anti-Bclx L (1:1000; Cell Signaling Technology), anti-GAPDH (1:2000; clone 14C10; Cell Signaling Technology), anti-SFPQ (1:1000; clone 6D7; Sigma-Aldrich), anti-Phospho-IP 3 R1 Ser1756 (1:500; clone D10E3; Cell Signaling), and anti-IP 3 R1
Fisher Scientific) and probed with the following antibodies: anti-His (1:1000; Novagen) and anti-pan-Actin (1:1000; Cell Signaling Technology). To confirm peptide uptake, cultures were processed for axonal degeneration assay as above, and FITC immunofluorescence was examined with a 40X air objective. Paclitaxel was added to cultures 1 hr after protein or peptide transfection.
Neurotrophin-deprivation FITC-SAHBs (Bclw, Bcl2, and Bclx L or no peptide control; 350ng) were transfected into the cell body compartment of compartmented cultures using the Chariot system as described above. One hour later, both cell body and axon compartments were changed into media without NGF + BDNF for 24 hr. A non-transfected control culture was maintained in 100 ng/mL NGF + BDNF media. Cultures were fixed and incubated with DAPI (1:1000). Images were taken with a 40x air objective, and an observer blind to condition counted the number of total and condensed nuclei using NIH ImageJ software.
Calpain protease activity luminescence assay For paclitaxel dose response assay, DRG neurons in mass cultures were treated with paclitaxel (30 nM, 600 nM, or 1.2 mM for 48 hr), calcium chloride (3 mM for 24 hr), or vehicle control (0.1% DMSO for 48 h). For Bcl2 family rescue assay, DRG neurons in mass cultures were transfected using the Chariot system as above with His-tagged Bclw, Bcl2, and Bclx L proteins or untransfected control, then treated for 24 hr with 600 nM paclitaxel or vehicle control. Cultures were harvested in 1x Passive Lysis Buffer (Promega). Lysate was spun 10,000xg for 5 min at 4 C, and 50 mL supernatant was combined with 50 mL Calpain-Glo Reagent (Promega) in a 96 well plate. Plate was shaken briefly and incubated 40 min in the dark; luminescence intensity was measured with a microplate reader and normalized to protein concentration.
Biotinylated SAHB pull-downs E15 DRG neurons were grown in compartmented chamber cultures for 7-8 days, and cell bodies and axons were separately harvested in lysis buffer containing 1% CHAPS detergent, 150 mM NaCl, 50 mM Tris pH 7.4, 1 mM DTT, 1 mM NaF, 0.1 mM PMSF, 0.1 mM Na 3 VO 3 , and EDTA-free cOmplete Mini protease inhibitor cocktail (Sigma-Aldrich). Lysate was pre-cleared 2 hr at 4 C with High Capacity Neutravidin Agarose Beads (1:20 in lysate; Thermo Scientific). For each pull-down, 200-600 mg of precleared lysate was incubated overnight at 4 C with biotin alone or with biotinylated-BH4 SAHB peptides of Bclw, Bcl2, or Bclx L to a final peptide or biotin concentration of 20 mM. The next day, Neutravidin beads were added (1:14) to lysate for 2 hr at 4 C. Lysate was removed, beads were washed on ice with cold PBS + protease inhibitor cocktail, and sample was eluted by boiling for 5 min in non-ionic lysis buffer, sample buffer, and reducing agent. Protein was resolved with either 4%-12% Bis-Tris SDS-page (Bax, YARS, IP 3 R1) or 3%-8% Tris-Acetate SDS-page (YARS, IP 3 R1) and probed with the following antibodies: anti-Bax (1:1000; Cell Signaling), anti-YARS (1:500; tyrosyl tRNA synthetase; clone EPR9927; Abcam), and anti-IP 3 R1 (1:1000; Thermo Scientific). YARS was used as a negative control as this protein is present at similar levels in axons and cell bodies. A 10% input lane from the original cell body or axon lysate was run alongside pull-down lysate. Band intensity was quantified as described above, and each pull-down intensity was normalized to the input intensity.
Calcium imaging E15 DRG neurons in microfluidic devices were infected on DIV0 with AAV9-GCaMP6s (AAV9.CAG.GCaMP6s.WPRE.SV40) and AAV9-mCherry (AAV9.CB7.CI.mCherry.WPRE.rBG) for 24 hr (Penn Vector Core). After 4-5 days, 600 nM paclitaxel or vehicle control (0.1% DMSO) were added to both cell body and axon compartments for 24 hr. Cultures were incubated 15 min (37 C, 7.5% CO 2 ) in calcium-free media (130 mM NaCl, 4.7 mM KCl, 2.3 mM MgSO 4 , 1.2 mM KH 2 PO 4 , 10 mM EGTA, 20 mM HEPES pH 7.3, 5 mM Glucose), then imaged with a Nikon Ti-E at 37 C (60x oil 1.4NA objective) while cells bodies were stimulated with 200 mM ATP (Sigma-Aldrich) or 5 mM thapsigargin (Thermo Fisher Scientific) in calcium-free media. For two fields of view, GCaMP6s and mCherry channels were acquired every 5 s for 60 s, then every 20 s for 440 s. ATP or thapsigargin was added after 15 s of baseline measurements. Images were analyzed using NIH ImageJ software. For each individual cell at each time point, a mask was generated from mCherry channel; GCaMP6s and mCherry fluorescence intensities were measured; and background fluorescence was subtracted. The change in fluorescence (DF/F) was calculated per cell according to the equation [(F -F0)/F0)] where F0 is the average baseline fluorescence at time 0-15 s and F is the recorded fluorescence for a given experimental time point. For ATP stimulation, 119 (paclitaxel) and 156 (vehicle) neuronal cell bodies were measured across 3 independent experiments with 3 cultures per experiment. For thapsigargin stimulation, 196 (paclitaxel) and 233 (vehicle) neuronal cell bodies were measured across 3 independent experiments with 3 cultures per experiment.
Cytochrome c immunostaining E15 DRG neurons grown in microfluidic cultures were treated with 60 nM paclitaxel to the axonal compartment for 48 hr and mitochondria were labeled with 200 nM MitoTracker Red CMX ROS (Thermo Fisher Scientific) in media for 15 min at 37 C, washed with HBSS, and incubated 1 min with an ice cold methanol wash before fixation with 4% PFA for 15 min. Cultures were stained as above with anti-cytochrome c (1:100; clone 6H2.B4; Thermo Fisher Scientific). Images were acquired throughout the axon compartment. Colocalization was quantified in ImageJ by doing a background subtraction and using the JACoP plugin (Bolte and Cordeliè res, 2006) to calculate the thresholded Mander's overlap coefficient (tMOC) representing the fraction of cytochrome c overlapping MitoTracker-labeled mitochondria. An intensity threshold for each channel was set manually for each experiment based on a control image. 15 (paclitaxel) and 14 (vehicle) images were measured across 3 independent experiments. As a positive control for induction of cytochrome c release, cultures were treated globally with 200 nM K252a in media lacking neurotrophins for 48 hr, and a reduction in tMOC was confirmed.
Paclitaxel treatment and behavioral testing 2 month old age-matched bclwÀ/À and bclw+/+ mice (17-30 g) of both sexes were injected intraperitoneally (IP) with 4 mg/kg paclitaxel (Bristol-Myers Squibb) every other day for 8 days (4 total injections). Equivalent ratio of males to females was used in each group and sex did not alter the results. Paclitaxel was prepared as 1 part 6 mg/mL paclitaxel stock solution diluted in vehicle (1:1 v/v Cremophor EL [EMD Millipore] and dehydrated ethanol) and 2 parts sterile saline and injected at 10 mL/g. Control mice were injected with 1 part vehicle and 2 parts saline. At 4-6 months of age bclwÀ/À mice have altered noxious thermosensation; however 2-3 month old bclwÀ/À mice exhibit normal motor function and noxious sensation (Courchesne et al., 2011) . For three days prior to the baseline testing, mice were weighed, trained on an automated RotaRod apparatus (4 rpm for 1 min without falling), and habituated in von Frey cages. The next two days, baseline behavioral performance was assessed and averaged. The first paclitaxel injection was given three days later, and mice were weighed and behaviorally tested 10 days after the final injection. Noxious mechanosensation threshold was assayed as described previously (Courchesne et al., 2011) using von Frey filaments (0.008-1.4g). Withdrawal threshold was determined to be the applied force at which the animal withdrew the stimulated paw on at least 2 of 10 applications. Noxious thermal sensation threshold was assayed as described previously (Courchesne et al., 2011 ) using a 50 C hotplate and measuring latency to withdraw the hindpaw. To assay motor function, mice were placed on the RotaRod with a ramp of 4-40 rpm and 0.4 rpm/s acceleration, and latency to fall was measured. Mouse behavior was assessed by an experimenter blind to genotype and condition.
Epidermal footpad innervation
Footpad tissue from hindpaws of bclwÀ/À and bclw+/+ mice was harvested, fixed, and sectioned as done previously (Cosker et al., 2013) . Briefly, mice were euthanized with isoflurane 11 days after final paclitaxel injection and footpad tissue was removed and divided into thick (dermal papillae containing) and thin (non-dermal papillae containing) skin. Footpads were fixed in Zamboni's fixative overnight at 4 C, cryopreserved in 30% sucrose overnight at 4 C, frozen, and sectioned into 30 mm floating sections. Sections were blocked in 10% normal goat serum with 0.1% Triton X-100 in PBS 1 hr at room temperature and incubated with anti-Tuj1 (1:300; Covance) overnight at 4 C. Sections were then incubated with goat anti-mouse AlexaFluor 488 (1:200; Invitrogen) and DAPI (1:1000) for 2 hr at room temperature and mounted on gelatin-coated slides. Epidermal images were acquired on a Nikon Ni-E C2 confocal with a 40x 1.3NA oil objective as 30-35 mm z stacks (1 mm step size) and converted into a maximum intensity projection image. Intraepidermal nerve fiber density was determined to be the number of Tuj1-positive fibers penetrating R 10 mm into the epidermis, normalized to the measured epidermal length (225-450 mm per image) and displayed as number of Tuj1-positive fibers per 225 mm. Images were acquired and quantified in NIH ImageJ by an experimenter blind to genotype and condition.
QUANTIFICATION AND STATISTICAL ANALYSIS
Data are expressed as mean + SEM or ± SEM. To assess statistical significance, data were analyzed by unpaired two-tailed Student's t test. Calcium imaging experiments were analyzed by two-way ANOVA with post hoc Bonferroni correction. For all other multiple comparisons, data were analyzed by one-way ANOVA with post hoc Bonferroni or Dunnett correction unless otherwise indicated. Significance was placed at p < 0.05 unless otherwise indicated. Statistical analysis was done using Microsoft Excel and GraphPad Prism.
